[HTML][HTML] EGFR and COX-2 dual inhibitor: the design, synthesis, and biological evaluation of novel chalcones
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
[PDF][PDF] EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari… - …, 2022 - pdfs.semanticscholar.org
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari, NH Alotaibi… - agris.fao.org
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones.
A Musa, EM Mostafa, SNA Bukhari, NH Alotaibi… - …, 2022 - search.ebscohost.com
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
[HTML][HTML] EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari, NH Alotaibi… - Molecules, 2022 - ncbi.nlm.nih.gov
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
[PDF][PDF] EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari, NH Alotaibi… - Molecules, 2022 - academia.edu
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari… - Molecules (Basel …, 2022 - pubmed.ncbi.nlm.nih.gov
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari, NH Alotaibi… - …, 2022 - search.proquest.com
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
[PDF][PDF] EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
A Musa, EM Mostafa, SNA Bukhari, NH Alotaibi… - …, 2022 - researchgate.net
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones.
A Musa, EM Mostafa, SNA Bukhari… - Molecules (Basel …, 2022 - europepmc.org
For most researchers, discovering new anticancer drugs to avoid the adverse effects of
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …
current ones, to improve therapeutic benefits and to reduce resistance is essential. Because …